HODLP: First International Inter-Group Study for Nodular Lymphocyte Predominant Hodgkin's Lymphoma in Children and Adolescents


Leukemias / Lymphomas : Lymphocyte predominant Hodgkin lymphoma


Hodgkin lymphoma (HL) is a type of cancer of the lymph system, a cancer that begins in cells of the immune system. The immune system fights infections and other diseases. There is a specific type of HL known as Lymphocyte Predominant Hodgkin Lymphoma (LPHL). The lymph system is made up of tissue in the body that makes cells that fight infection. HL is one of the most treatable and curable childhood cancers.

The standard treatment for HL is chemotherapy, radiation therapy (high-dose x-rays) or a combination of both. Although treatment of the cancer is very effective, the treatment can cause problems later in life. These kinds of side effects are often called “late effects.” Late effects can include problems with growth, organ function, and sometimes a second kind of cancer. Late effects may be caused by both chemotherapy and radiation. Researchers believe that if some people can be treated with less therapy or with surgery alone, then these people may have fewer late effects. The standard treatment for LPHL in children is chemotherapy with or without radiation therapy (high-dose x-rays), depending on stage of disease.


The main goal of this study is to find out if treatment for childhood LPHL can be further improved to avoid over-treatment and decrease long-term complications from therapy, while maintaining or improving response and survival rates previously seen with standard therapy.


For the current eligibility status of this clinical study, referring physicians must contact St. Jude Children's Research Hospital at 1-866-2ST-JUDE (1-866-278-5833).


Monika Metzger, MD
St. Jude Children’s Research Hospital
262 Danny Thomas Place
Memphis, TN 38105 USA
Voice: 1-866-2ST-JUDE (1-866-278-5833)
FAX: 901-595-5068

Referring or consulting physicians only:

For all other inquiries about St. Jude Children's Research Hospital studies:

The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.